H
Helong Zhang
Researcher at Fourth Military Medical University
Publications - 99
Citations - 2378
Helong Zhang is an academic researcher from Fourth Military Medical University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 81 publications receiving 1235 citations.
Papers
More filters
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Yuankai K. Shi,Lvhua Wang,Baohui Han,Wei Li,P. Yu,Y. Liu,Cuimin Ding,X. Song,Z. Y. Ma,X. L. Ren,J. F. Feng,Helong Zhang,Gong Yan Chen,Xiaohong Han,Ning Wu,C. Yao,Yinglin Song,Shu Cai Zhang,Wei Song,Xiaoqing Liu,S. J. Zhao,Y. C. Lin,X. Q. Ye,Kai Li,Y. Q. Shu,L. M. Ding,F. L. Tan,Y. Sun +27 more
TL;DR: First-line icotinib significantly improves PFS of advanced lung adenocarcinoma patients with EGFR mutation with a tolerable and manageable safety profile and should be considered as a first-line treatment for this patient population.
Journal ArticleDOI
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial
Huiyan Luo,Huiyan Luo,Jin Lu,Yuxian Bai,Teng Mao,Jun Wang,Qingxia Fan,Yiping Zhang,Kuaile Zhao,Zhendong Chen,Shegan Gao,Jiancheng Li,Zhichao Fu,Kangsheng Gu,Zhihua Liu,Lin Wu,Xiaodong Zhang,Jifeng Feng,Zuoxing Niu,Yi Ba,Helong Zhang,Ying Liu,Li Zhang,Xuhong Min,Jing Huang,Ying Cheng,Dong Wang,Yu Shen,Qing Yang,Zou Jian-Jun,Rui-Hua Xu,Rui-Hua Xu,Escort st Investigators +32 more
TL;DR: The ESCORT-1st trial as discussed by the authors evaluated the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as a first-line treatment in advanced or metastatic esophageal squamous cell carcinoma.
Journal ArticleDOI
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Shukui Qin,Feng Bi,Shanzhi Gu,Yuxian Bai,Zhendong Chen,Zishu Wang,Jieer Ying,Yinying Lu,Zhiqiang Meng,Hongming Pan,Ping Yang,Helong Zhang,Xi Chen,Aibing Xu,Chengxu Cui,Bo Zhu,Jian Wu,Xiaoli Xin,Jufeng Wang,Jinlu Shan,Junhui Chen,Zhendong Zheng,Li Xu,Xiaoyu Wen,Zhenyu You,Zhenggang Ren,Xiufeng Liu,Meng Qiu,Liqing Wu,Feng Chen +29 more
TL;DR: In this article, a multikinase inhibitor and a deuterated sorafenib derivative were compared in phase Ia and Ib hepatocellular carcinoma (HCC) studies.
Journal ArticleDOI
Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting γ-synuclein.
Yafang Wang,Xiangqiang Liu,Hongbo Zhang,Li Sun,Yongan Zhou,Haifeng Jin,Hongwei Zhang,Hui Zhang,Jiaming Liu,Hao Guo,Yongzhan Nie,Kaichun Wu,Daiming Fan,Helong Zhang,Lili Liu +14 more
TL;DR: The results advance the understanding of the role of lncRNA-AK058003 as a regulator of hypoxia signaling, and this newly identifiedhypoxia/lnc RNA-AK58003/SNCG pathway may help in the development of new therapeutics.